EE256 Cost-Utility Analysis of Lorlatinib in First-Line Treatment of adult patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (aNSCLC) in Colombia
Abstract
Authors
Jair A. Arciniegas Diego M. Gonzalez Ricardo Bruges Andreina J. Alamo Steffy Pardo Juan Manuel Reyes Sanchez